Cochrane · systematic review · CD007189
Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals
Okwundu, CI, Uthman, OA, Okoromah, CAN · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
HIV/AIDSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
TDF+ FTC compared to placebo for preventing HIV in high‐risk individuals
Population: High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV infection TDF+ FTC vs placebo | RR 0.49 [0.28, 0.85] | 4 studies · 8813 participants | Moderate |
Serious adverse events TDF+ FTC vs placebo | RR 1 [0.83, 1.19] | 3 studies · 6862 participants | Moderate |
TDF compared to placebo for preventing HIV in high‐risk individuals
Population: High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV infection TDF vs placebo | RR 0.33 [0.2, 0.55] | 2 studies · 4027 participants | Moderate |
Serious adverse events TDF vs placebo | RR 1.03 [0.79, 1.33] | 1 study · 3168 participants | Moderate |